Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2011

View Archived Issues

Pfizer synthesizes novel MAP kinase-activated protein kinase 2 inhibitors

Small-molecule DMART ameliorates SLE-like symptoms in vivo

Portola's recombinant factor Xa inhibitor antidote reverses rivaroxaban effects in vivo

New PLK1-inhibiting pyrimidodiazepinone derivatives identified

ApoA-I production enhancer reduces inflammatory biomarkers in CAD and may affect HDL functionality

Jasco Pharmaceuticals discloses novel casein kinase inhibitors

Phase II HQK-1001 trial in sickle cell disease fully enrolled

New voltage-gated sodium channel blockers synthesized at Amgen

Medivation presents novel neurotransmitter modulators

Juvaris and Colby Pharmaceutical enter agreement for CLDC technology and JVRS-100

Arch Biopartners selects lead agent for development in NSCLC and pancreatic cancer

New agents for viral infections patented by U.S. researchers

Ampla Pharmaceuticals describes novel IL-1 beta inhibitors

Pharmasset initiates screening for QUANTUM trial

OPA-6566 enters clinical development

Acceleron Pharma begins first-in-human study of ACE-536

Hawthorn Pharmaceuticals and CoPlex Therapeutics enter licensing deal

Ono Pharmaceutical set to launch Corebeta in Japan

Antisense Therapeutics begins multiple-dose stage of phase I ATL-1103 trial

Seattle Genetics and Oxford BioTherapeutics form antibody-drug conjugate collaboration

Abbott begins phase II study in uterine fibroids

Amicus and GSK initiate second phase III registration study of Amigal

Lexicon's antidiabetes candidate LX-4211 affects multiple parameters of glycemic control

Ono Pharmaceutical enters agreement with Servier for ivabradine

MorphoSys achieves second clinical milestone in anticancer antibody program with Bayer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026